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Multicopy Suppressors for Novel
Antibacterial Compounds Reveal Targets
and Drug Efflux Susceptibility
pound to the intracellular space of a bacterial or fungal
cell are poorly understood. Nevertheless, there is grow-
ing appreciation that small molecule permeability in bac-
teria is governed to an extent by ubiquitous multidrug
efflux pumps [6], whose substrate specificities are very
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McMaster University broad and hard to define [7]. Hence phenotype-based
screens have a particular advantage in that bioactive1200 Main Street West
Hamilton, Ontario L8N 3Z5 molecules identified already have physical-chemical
properties that are compatible with microbial cell perme-Canada
ation. What are needed, however, are robust forward
genetic approaches for the identification of protein tar-
gets of small molecules identified in phenotype-basedSummary
small molecule screens of microbes.
Since the availability of the first plasmid-encoded ge-Gene dosage has frequently been exploited to select
nomic libraries [8], geneticists have exploited the effectsfor genetic interactions between a particular mutant
of increasing gene dosage to identify genetic interac-and clones from a random genomic library at high
tions. The technique is referred to as high-copy orcopy. We report here the first use of multicopy sup-
multicopy suppression and involves the creation of apression as a forward genetic method to determine
plasmid-encoded random genomic library followed bycellular targets and potential resistance mechanisms
a selection or screen for clones that have a suppressorfor novel antibacterial compounds identified through
phenotype. More recently, multicopy suppression hashigh-throughput screening. A screen of 8640 small
found utility in the identification of genes capable ofmolecules for growth inhibition of a hyperpermeable
suppressing the activity of antibiotics with antibacterialstrain of Escherichia coli led to the identification of 49
[9, 10], antifungal [11–14], and antiparasitic [15, 16] activ-leads for suppressor selection from clones harboring
ities. High-copy suppressors have likewise been identi-an E. coli genomic library. The majority of suppressors
fied for anticancer drugs [17]. From these studies it iswere found to encode the multidrug efflux pump AcrB,
understood that overexpression of a protein will oftenindicating that those compounds were substrates
lead to resistance to the chemotherapeutic agent owingfor efflux. Two leads, which produced clones contain-
to two general mechanisms. In one mechanism, perhapsing the gene folA, encoding dihydrofolate reductase
the most common, overexpression of a protein involved(DHFR), proved to target DHFR in vivo and were com-
in the modification or efflux of the chemotherapeuticpetitive inhibitors in vitro.
agent leads to suppression of the lethal phenotype. Al-
ternatively, overexpression of the protein target itself
Introduction can lead to resistance. Multicopy suppression has thus
found some utility in identifying suppressors of the ac-
Phenotype-based screens for small molecules with bio- tion of pharmaceutical agents of unknown mechanisms.
logical activity have accounted for an overwhelming We report here on the first use of multicopy suppression
majority of pharmaceutical drugs in use today and are as a forward chemical genetic method to determine cel-
finding increasing use in a chemical biology research lular targets and potential resistance mechanisms, par-
paradigm emerging in academic circles. The latter in- ticularly efflux, for novel antibacterial leads identified
cludes a number of recent examples of success in the with high-throughput screening.
discovery and optimization of novel molecules found in
synthetic and natural product libraries that function as
powerful probes of biological systems (reviewed in Results
[1–4]). Such efforts have been punctuated by the ambi-
tious goal of one selective, cell-permeable small mole- Screening for Growth Inhibitory Small Molecules
cule ligand for every protein in a cell [5]. Our work began with a high-throughput screen to iden-
One of the most significant hurdles to the use of phe- tify compounds in a small molecule screening library
notype-based small molecule screens is the identifica- (8640 molecules) that had growth inhibitory activity
tion of the macromolecular target in the cell. In contrast, against E. coli strain MC1061, a hyperpermeable rough
the discovery and optimization of inhibitors of protein lipopolysaccharide mutant [18], at a concentration of 50
function using target-based biochemical screens is M in rich liquid media. The compound library was from
plagued with dilemma of ultimately creating molecules Maybridge plc (Cornwall, England), had an average mo-
that penetrate and persist in cells in order that they lecular mass of 325 g/mol, and was chosen for its high
have biological activity. Nowhere is the issue of cell quality, diversity, drug likedness, and resupply rate [19].
permeability more acute than in antimicrobial research Figure 1 shows a replicate plot of the screening data
where the principles governing access of a given com- where the quality of the screen is evident in the high
correspondence of duplicate determinations. We calcu-
lated Z statistical values of 0.78 and 0.73 for repli-*Correspondence: ebrown@mcmaster.ca
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Figure 1. Primary Screen for Compounds with Growth Inhibitory
Activity
Shown is a replicate plot for the test wells of a duplicate screen of
8640 compounds. Growth in the test wells is expressed as percent-
age of that in control wells. A total of 301 actives were identified in
the hit zone (gray inset) that was established at a threshold of 75%
growth relative to the control wells. Figure 2. Outline of Screening Process
cates 1 and 2, respectively. Z is a measure of the quality retarding concentrations of each novel molecule, we set
of a small molecule screening campaign [20] and is de- about to select for suppressors using a pool of clones
fined as harboring a multicopy genomic library of E. coli.
Z  1 
(3c  3c)
|c  c|
, (1) Selection for Multicopy Suppressors
As proof of principle we first selected for suppressors
of the activity of three well-known antibiotics. Figure 3where c, c, c, and c are the standard deviations
() and averages () of the high (c) and low (c) controls. shows a typical experiment where we systematically
exposed a control strain and a pool of clones harboringThe Z value also suggests that this was a high-quality
screen since a Z of 0.5 or greater is indicative of a data the genomic library to increasing concentrations of the
antibiotic trimethoprim. While growth inhibition waswith an acceptable signal window and errors associated
with the high and low controls. Molecules that demon- seen in the control at 0.078 g/ml of trimethoprim, sup-
pressor clones were evident at almost ten times thatstrated 25% growth inhibition were judged to be hits
in the primary screen resulting in the selection of 301 concentration (0.64 g/ml). Similarly, suppressors were
isolated for growth inhibition by cycloserine and fosfo-compounds (3.5% hit rate) for further analysis.
Figure 2 summarizes the approach to arrive at a small mycin (Table 1). Sequencing of the plasmid DNA con-
tained in these clones revealed inserts in the cloningnumber of growth inhibitory leads for multicopy sup-
pression and subsequent follow up. Of the 301 com- site of pGEM7 corresponding to genomic fragments en-
coding the targets of these three antibiotics. Trimetho-pounds selected from primary screening, 196 showed
complete growth inhibition on rich solid media at 500 prim produced clones with the fragment yabF-kefC-folA
where folA encoding dihydrofolate reductase is the tar-M. This secondary screen was necessarily on solid
media and at a higher concentration to test for complete get of trimethoprim [21]. Fosfomycin yielded the frag-
ment ispB-sfsB-murA-yrbA where murA encodes itsinhibition of growth because of the nature of down-
stream multicopy suppression experiments. Those ex- target UDP-N-acetylglucosamine enolpyruvyltransfer-
ase [22]. Cycloserine yielded two different clones con-periments required the selection and isolation of clones
resistant to otherwise lethal concentrations of the leads taining the fragments yaiW-yaiY-YaiZ-ddlA-yaiB-phoA-
psiF and yaiY-YaiZ-ddlA-yaiB where ddlA encodes theand where the minimum inhibitory concentrations (MIC)
of the leads were frequently in the range of 50–500 M. target D-ala-D-ala ligase [23].
Of the 49 leads selected from our screen for novelClassification of these 196 molecules according to
structural features facilitated the selection of a represen- growth inhibitory molecules, suppressor clones could
be isolated for 33 of the compounds, while the remaindertative subset of 49 leads for further analysis. Subsequent
MIC analysis on these 49 leads revealed the mini- of the compounds simply did not produce resistant
clones. Clones suppressing the activity of two of themum concentration necessary to inhibit bacterial growth
for each active molecule. Having established growth- compounds, 1a and 2a, were found to contain folA en-
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plasmid in an E. coli host, strain CW2553 containing
pAK01, that allowed for incremental control of protein
expression [26]. With this system, increasing inducer
concentrations led to a steady increase in MIC for the
control molecule trimethoprim without any impact on
the MIC for tetracycline (Figure 4A). Similarly, the MIC
values for 1a and 2a demonstrated an inducer depen-
dence (Figure 4B) that was consistent with the conclu-
sion that growth inhibition by these molecules was due
to inhibition of DHFR.
2,4-Diaminopyrimidine- and 2,4-Diaminoquinazoline-
Containing Analogs
Compounds 1a and 2a can be broadly classified as 2,4-
diaminopyrimidine- and 2,4-diaminoquinazoline-con-
taining molecules, respectively, where trimethoprim falls
into the former structural class. Interestingly, we pre-
viously reported on the discovery of such molecules in
a biochemical screen of 50,000 small molecules against
recombinant E. coli DHFR [27], where the 8,640 com-
pound library used in this work was a subset of those
screened for inhibition of the enzyme. In the work re-
ported here, we have sampled analogs of 1a and 2a from
our compound library that were previously identified as
inhibitors of DHFR activity and characterized these for
their MIC and for their kinetic inhibition constants (Table
2). The latter involved a systematic analysis of the
steady-state kinetic behavior of DHFR at a range of
dihydrofolate and inhibitor concentrations to reveal
competitive inhibition mechanisms for all of the diamino-
pyrimidines (including trimethoprim) and diaminoquina-
Figure 3. Identification of Suppressor Clones for the Growth Inhibi- zolines (data not shown). The diaminopyrimidines 1a
tory Activity of Trimethoprim and 1b differ by only a methyl group, have comparable
Shown are petri plates from a proof of principle suppression experi- Ki values (1.0 and 1.1 M, respectively), and showed a
ment where 105 cells of E. coli MC1061 were exposed to increasing 4-fold difference in MIC (16 and 64 g/ml). Likewise, the
concentrations of trimethoprim in LB-Str-Amp agar. The cells were
MIC values of the diaminoquinazolines 2a, 2b, 2c, andfrom a selection pool, containing a multicopy genomic library cloned
2d did not track with Ki. For example, 2a and 2d differinto pGEM7, and a control pool, containing empty vector pGEM7.
in the bridging position Y (O or S, respectively) and inSuppressors were those clones from the library showing resistance
not seen in the control pool. These colonies were found to contain the phenyl substitution Z (CH3 and Cl, respectively) and
identical clones containing DNA coding for the neighboring genes demonstrated a greater than 6-fold difference in affinity
yabF, kefC, and folA at the cloning site of pGEM7. (230 and 38 nM, respectively) but had identical MIC
values of 4 g/ml. The lack of correspondence of MIC
and Ki values seen here, despite minor variations incoding DHFR (Table 1). While all of the suppressors
structure, is illustrative of a common difficulty in antimi-isolated for the activity of 1a contained the gene folA,
crobial research of translating gains in biochemical inhi-two different suppressors isolated for 2a and at a similar
bition into increased cellular potency.frequency. Those suppressors contained either folA or
acrB, encoding the membrane component of the acri-
dine efflux pump [24]. Indeed, all of the suppressors Quantitative Analysis of Suppression by folA
and acrB Containing Clonesthat were isolated for the remaining 31 molecules con-
tained a clone with a single open reading frame for acrB Struck by the frequency with which we isolated suppres-
sors containing the multidrug efflux pump, acrB, wein the cloning site of pGEM7. We reasoned that the
antibacterial action of these compounds was abrogated endeavored to make a comparative analysis of the sup-
pression of the activity of compounds 1a, 2a, and ana-by overexpression of this cellular pump from the high-
copy plasmid pGEM7 resulting in resistance to other- logs by clones containing acrB and folA. Figure 5 shows
the fold suppression of the activity of these moleculeswise toxic molecules.
by clones containing pGEM7-acrB and pGEM7-yabF-
kefC-folA relative to a clone containing empty vectorGrowth Inhibition Is Dependent on the Expression
of Dihydrofolate Reductase pGEM7. The controls trimethoprim and ciprofloxacin
showed selective suppression as expected by clonesTo further confirm that the antibacterial activities of
compounds 1a and 2a were related to inhibition of encoding folA and acrB, respectively. Suppression of
the activity of ciprofloxacin, for example, was 4-foldDHFR, we subcloned folA into an arabinose inducible
expression system, vector pBAD18 [25], and placed this by the pGEM7-acrB-containing clone, consistent with
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Table 1. Outcome of Selections for Multicopy Suppressors for Controls and Two Test Compounds
Compound MICa (g/ml) Suppressor Clonesb
Fosfomycin 80 ispB-sfsB-murA-yrbA
Trimethoprim 0.078 yabF-kefC-folA
Cycloserine 80 (i) yaiW-yaiY-YaiZ-ddlA-yaiB-phoA-psiF
(ii) yaiY-YaiZ-ddlA-yaiB
16 yabF-kefC-folA
1a
(i) yabF-kefC-folA
4.0
(ii) acrB
2a
a Minimum growth inhibitory concentrations (E. coli MC1061/pGEM7) for the compounds indicated. Cells were grown on LB agar containing
ampicillin (50 g/ml) and streptomycin (50 g/ml).
b Indicated are the identities of compete open reading frames present in the cloning site of pGEM7 found by sequencing suppressor clones
isolated from the random genomic library. In the case where two types of suppressor clones were identified they are listed (i) and (ii).
a well-documented role for acrB in fluoroquinolone re- coded genome-wide heterozygous yeast strains was
recently used to identify mutants that fail to grow insistance [6]. Given that compound 1a failed to select
for clones containing acrB in our high-copy suppression the presence of growth inhibitory drugs [33, 34]. The
procedure, termed drug-induced haploinsufficiency,screen, it is perhaps not surprising that we saw no sup-
pression by pGEM7-acrB and 8-fold suppression with has been shown to be effective in identifying the targets
of well-characterized clinical and agricultural agents.the folA-containing clone. Compound 1b, on the other
hand, differs only by a methyl group and showed a 4-fold Most recently, Parsons et al. [35], using the complete
set of yeast haploid deletion mutants, generated drug-suppression by acrB. The diaminoquinazoline 2a, showed
an equal propensity to produce clones encoding folA hypersensitivity profiles for 12 compounds to identify
target proteins, pathways, and multidrug resistanceand acrB in our multicopy suppression selection. Com-
pound 2a likewise demonstrated a 4-fold suppression mechanisms.
Here we report on the first use of multicopy suppres-with clones containing either pGEM7-yabF-kefC-folA or
pGEM7-acrB, and similar behavior was evident with the sion to identify the targets of novel antibacterial com-
pounds discovered with high-throughput screening. Un-diaminoquinazoline analogs 2c and 2d. In contrast, the
acrB-containing clone showed no capacity for sup- like genomic methods that require extensive screening
of transcripts, such as transcriptional profiling, multi-pressing the activity of analog 2b while demonstrating
64-fold suppression by folA at high copy. copy suppression is a selection procedure that facili-
tates the rapid identification of target-encoding clonesWhile there have been no systematic investigations
of the substrate specificity of acrB, the anecdotal evi- among suppressors. Proof of principle for this system
has been achieved with the isolation of genes encodingdence [6] and that of recent costructures of four such
ligands with AcrB [7] have pointed to compound hydro- the targets of known antibiotics and of novel antibacte-
rial leads. The isolation of multicopy suppressors har-phobicity as an important determinant. In data not
shown, we examined the fold suppression of growth boring folA encoding DHFR with two antibacterial mole-
cules 1a and 2a highlights the feasibility of the approach.inhibition by acrB at high copy (pGEM7-acrB) for all 49
growth inhibitory compounds short listed in this work Derived from a screen for growth inhibition of just 8640
small molecules from a diverse commercial library, theseand noted a positive correlation between fold suppres-
sion and calculated LogP, a commonly used molecular molecules and their analogs represent novel leads with
well-behaved permeability characteristics that inhibit adescriptor for general hydrophobicity [28].
validated antibacterial target.
Surprising to us, nevertheless, was the frequency withDiscussion
which we selected clones using multicopy suppression
that contained acrB encoding a multidrug efflux pump.Classically, the identification of protein targets for phe-
notype-perturbing small molecules has been accom- Multidrug efflux pumps are understood to have a role in
protecting most living cells from action of cell permeableplished biochemically using labeled or immobilized mol-
ecules. Recent advances in forward chemical genetic and toxic molecules. The AcrB protein is a proton-ener-
gized drug efflux pump of broad and poorly understoodapproaches have included DNA [29] and protein [30]
microarrays, three-hybrid systems [31], and compound substrate specificity that is well known as a menacing
clinical problem in bacterial infections [6, 36]. In Gram-library annotation by biological mechanism profiling
[32]. A competitive growth assay using a pool of bar- negative pathogens, in particular, increased expression
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is consistent with the conventional view that hydrophi-
licity is an important permeability characteristic.
In conclusion, we suggest that multicopy suppression
is a workable forward genetic method to isolate tar-
gets for small molecules identified in phenotype-based
screening. The approach is clearly generalizable to a
wide variety of experimental systems, including the dis-
covery of novel antifungal, antiparasitic, and anticancer
molecules and their targets. In the context of the anti-
bacterial screening campaign described, we predict that
on-going screening and suppression studies will con-
tinue to identify both targets and resistance genes for
novel antibacterial molecules. It is further suggested
that the capacity to select for suppressors with bona
fide targets in high copy, and not trivial resistance genes
such as multidrug efflux pumps, has implications for
the potential of any such molecule as a lead for new
antibacterial drugs.
Significance
Microbial genetic studies have frequently exploited
gene dosage to select for genetic interactions be-
tween a particular mutant and clones from a random
genomic library at high copy. This approach, termed
multicopy suppression, has likewise been used toFigure 4. Regulated Suppression of Growth Inhibition through Con-
identify resistance genes involved in efflux or modifi-trolled Expression
cation of chemotherapeutic agents and, less fre-Shown is the influence of MIC on the controlled expression of DHFR
quently, to identify the cellular targets of agents offrom an arabinose inducible promoter system pBAD18-folA in E. coli
CW2553 containing pAK01. unknown mechanism. We report here the first use of
(A) The arabinose dependence of the MIC in LB-Amp-Cmp broth of multicopy suppression as a forward chemical genetic
the positive control trimethoprim (open circles) compared to that method to determine cellular targets and potential re-
for the negative control tetracycline (closed circles). sistance mechanisms, for novel antibacterial com-
(B) Analogous data for compounds 1a (closed circles), 2a (closed
pounds identified with high throughput screening. Atriangles), and tetracycline (open circles). The constuct pBAD18-
high-throughput screen of 8640 small molecules forfolA was made as follows. Gene folA was amplified by PCR from
growth inhibitory activity toward a hyperpermeablegenomic DNA of E. coli MG1655 using the primers 5-C GCT CTA
GAT TTT TTT TAT CGG GAA ATC TCA ATG -3 and 5- CTA AAG strain of Escherichia coli resulted in the selection of
CTT TTA CCG CCG CTC CAG AAT C-3, containing XbaI and HindIII 49 lead molecules for analysis using multicopy sup-
restriction sites (underlined), respectively. The resulting product was pression. Selection from a pool of clones harboring a
cloned into the XbaI and HindIII site of pBAD18-Apr to create
random genomic library of E. coli revealed suppres-pBAD18-folA that puts the expression of gene folA under the control
sors of the antimicrobial activity of 33 of the com-of the arabinose promoter [25]. Controlled arabinose-inducible ex-
pression from plasmid pBAD18-folA was accomplished by transfor- pounds. The majority of these clones were found to
mation into E. coli strain CW2553 containing pAK01 [26]. contain a gene encoding the inner membrane compo-
nent of the multidrug efflux pump AcrB, indicating that
these compounds were substrates for efflux. Two
of AcrB orthologs is often associated with antibiotic compounds, one a 2,4-diaminopyrimidine and the other
resistance. Furthermore, basal levels of expression are a 2,4-diaminoquinazoline, gave rise to clones con-
increasingly thought to mediate intrinsic resistance to taining the gene folA, encoding dihydrofolate reduc-
antibacterial molecules. It is therefore tempting to spec- tase. Controlled expression of FolA in E. coli confirmed
ulate that the lion’s share of growth inhibitory molecules, that suppression of the activity of 2,4-diaminopyrimi-
for which we were unable to isolate suppressors other dines and 2,4-diaminoquinazolines was dependent on
than acrB (31 of the 33 molecules that yielded supres- dihydrofolate reductase levels, and steady-state en-
sors), might be structures that have inherently inferior zyme kinetics revealed that these compounds were
permeability characteristics. In that regard, it is notewor- competitive inhibitors of E. coli DHFR. The work illus-
thy that compounds 1a and 2b were apparently the trates the power of multicopy suppression as a for-
poorest substrates for efflux and therefore may provide ward chemical genetic method to reveal the mech-
the most intriguing leads among the diaminopyrimidines anism of action and efflux susceptibility of novel
or diaminoquinazolines examined in this study. Further- antibacterial leads. Finally, we believe that this ap-
more, the finding in this work that propensity for sup- proach is generalizable to a wide variety of systems
pression by AcrB correlates by and large with calculated including the discovery of novel antifungal, antipara-
sitic, and anticancer molecules and their targets.LogP, a gross molecular descriptor of hydrophobicity,
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Table 2. Analogs of 1a and 2a and Their Respective Antibacterial and Anti-DHFR Potencies
x y z MIC (g/ml) Ki (nM)
1a CH3 — — 100016
641b H — — 1100
2a — O CH3 4.0 230
2b — O F 16 180
2c — S CH3 8.0 150
2d — S Cl 4.0 38
Tmp — — — 0.03 3.0
Experimental Procedures 10 l of DMSO while the low control wells contained 50 g/ml
Ampicillin (Amp). Primary hits were defined as those compounds
that reduced growth by 25% compared to the high controls. ActivityPrimary Screening
The screen of Escherichia coli MC1061 (hsdR mcrB araD139 Base (v. 5.0.5, ID Business Solutions Limited, Emeryville, CA),
SARgen (v. 1.0, ID Business Solutions Limited), and Spotfire Deci-D(araABC-leu)7679 lacX74 galU galK rpsL thi) against 8640 small
molecules was fully automated with the use of a SAGIAN Core sionSite (v. 7.1.1, Spotfire Inc., Somerville, MA) were used for data
analysis.System (Beckman Coulter, Inc. Fullerton, CA) equipped with an
ORCA arm for labware transportation, a Biomek FX with a 96-chan-
nel head for liquid handling, and a Spectromax absorbance plate Secondary Screen and Lead Selection
reader (Molecular Devices Corp., Sunnyvale, CA); the entire system Hits from primary screening in liquid media were further analyzed
was integrated through SAMI software (v. 3.5, Beckman Coulter, in duplicate for growth inhibition on solid media. E. coli MC1061
Inc.). Incubations were done in duplicate and contained 50 M li- were grown overnight in LB-Str broth, diluted 105-fold, and 10 l/
brary compounds sourced from Maybridge plc (Cornwall, UK). E. coli well added into 96-well plates containing LB-Str agar (200 l/well).
MC1061 was grown overnight in Luria-Bertani (LB) broth containing Test wells contained compounds at 500 M (10 l of 5 mM com-
50 g/ml streptomycin (Str), diluted 105-fold in LB-Str broth, and pound in DMSO). High control wells contained 5% DMSO and low
deposited into 96-well microwell plate (200 l/well). To each test control wells, 50 g/ml Amp. Plates were incubated for 16 hr at 37 C
well, 10 l of screening compound (1 mM in DMSO) was added and before reading by visual inspection. Compounds causing complete
the plate incubated for 16 hr at 37C with shaking (150 rpm) before growth inhibition were clustered by chemical group functionality
reading the optical density (600 nm). High control wells contained and representative compounds were selected as leads for selection
experiments using multicopy suppression.
Multicopy Suppression
A random E. coli genomic library was a generous gift of Deborah
Siegele (Texas A&M University). The library was in the form of a
ligation mix, derived from a partial Sau3AI digest (3–4 kb gel-purified
fragments) of DNA from strain MG1655 cloned into the BamHI site
of pGEM7 (Promega, Madison, WI), and was transformed into E. coli
strain MC1061 and plated on LB-Str-Amp agar. Some 20,000 colo-
nies were picked from these plates after overnight growth (37C),
transferred to a single well in a 96-well plate containing 200 l LB-
Str-Amp broth, and grown overnight with shaking at 37C. Overnight
cultures were pooled, mixed with an equal volume of 30% glycerol
in LB broth, and stored in aliquots at 80C. The latter was referred
to as the selection pool. A control pool, E. coli strain MC1061 con-
taining pGEM7, was also grown overnight in broth LB-Str and was
subsequently mixed with an equal volume of 30% glycerol in LB
broth and was stored in aliquots at 80C.
Suppressor clones capable of growth in the presence of inhibitory
Figure 5. Suppression of Growth Inhibitory Activities of Compounds concentrations of compounds were selected using the following
1a, 2a, and Analogs by Suppressor Clones procedure. Typically, 105 bacteria from the control and selection
pools were plated on LB-Str agar with increasing concentrations ofThe plot shows fold suppression of growth inhibition by compounds,
1a, 2a, and analogs (structures are shown in Table 2) as well as a given compound. Plasmid DNA was prepared from clones in the
selection pool that were capable of growth at concentrations thatcontrols, Trimethoprim and Ciprofloxacin of E. coli MC1061 clones
harboring pGEM7-acrB (black bars) and pGEM7-yabF-kefC-folA were inhibitory to the control pool. Because many of the suppressor
clones were found to contain acrB, encoding the membrane span-(gray bars). Fold suppression for each clone was calculated from
MIC determinations (Experimental Procedures) for the compound ning subunit of the acridine efflux transporter [24], PCR was typically
used to screen plasmid DNA derived from suppressors prior toindicated in LB-Str-Amp and was relative to E. coli MC1061 con-
taining pGEM7. sequencing. This PCR screen employed the forward primer (5-ATG
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CTCCTCTAGACTCGAGGAATT-3) that annealed to the plasmid and 11. Launhardt, H., Hinnen, A., and Munder, T. (1998). Drug-induced
phenotypes provide a tool for the functional analysis of yeasta primer designed to anneal to acrB (5-TCAATGATGATCGACAG
TATGGCT-3). Plasmid DNA from PCR-negative clones were se- genes. Yeast 14, 935–942.
12. Tsukahara, K., Hata, K., Nakamoto, K., Sagane, K., Watanabe,quenced to determine the cloned insert using the pGEM7 forward
and reverse (5-GAATACTCAAGCTATGCATCCAAC-3) primers. Nu- N.A., Kuromitsu, J., Kai, J., Tsuchiya, M., Ohba, F., Jigami, Y.,
et al. (2003). Medicinal genetics approach towards identifyingcleotide-nucleotide BLAST was used to determine the portion of
genomic DNA cloned into pGEM7. the molecular target of a novel inhibitor of fungal cell wall assem-
bly. Mol. Microbiol. 48, 1029–1042.
13. Miura, N., Kaneko, S., Hosoya, S., Furuchi, T., Miura, K., Kuge,Minimum Inhibitory Concentration Determination
S., and Naganuma, A. (1999). Overexpression of L-glutamine:Determinations of minimum inhibitory concentration were made to
D-fructose-6-phosphate amidotransferase provides resistancecharacterize growth inhibition of test and control compounds as
to methylmercury in Saccharomyces cerevisiae. FEBS Lett. 458,well as to establish the degree of suppression by particular clones
215–218.selected from the genomic library. Typically, 105 E. coli MC1061
14. Calabrese, D., Bille, J., and Sanglard, D. (2000). A novel multi-cells were exposed to 2-fold dilutions of the compound from a stock
drug efflux transporter gene of the major facilitator superfamilysolution of 6.4 mg/ml in DMSO. Incubations were in LB broth using
from Candida albicans (FLU1) conferring resistance to flucona-96-well microwell plates (200 l/well) for 16 hr at 37C with shaking
zole. Microbiol. 146, 2743–2754.(150 rpm) before determining the optical density (600 nm). Concen-
15. Delling, U., Raymond, M., and Schurr, E. (1998). Identificationtrations where the optical density was less than 0.1 absorbance
of Saccharomyces cerevisiae genes conferring resistance tounits were deemed MIC.
quinoline ring-containing antimalarial drugs. Antimicrob. Agents
Chemother. 42, 1034–1041.Determination of Kinetic Inhibition Constants
16. Cotrim, P.C., Garrity, L.K., and Beverley, S.M. (1999). IsolationRecombinant E. coli DHFR was prepared and assayed as described
of genes mediating resistance to inhibitors of nucleoside andpreviously [27]. NADPH was constant at 80 M and dihydrofolate
ergosterol metabolism in Leishmania by overexpression/selec-was varied from 10 to 300 M. Data were analyzed using SigmaPlot
tion. J. Biol. Chem. 274, 37723–37730.version 8.0 software and fit to the Michaelis-Menten equation for
17. Burger, H., Capello, A., Schenk, P.W., Stoter, G., Brouwer, J.,competitive inhibition: V  Vmax 	 [S]/(KM 	 (1  I/Ki)  S).
and Nooter, K. (2000). A genome-wide screening in Saccharo-
myces cerevisiae for genes that confer resistance to the antican-Acknowledgments
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